Results 61 to 70 of about 7,154 (184)
MedComm, Volume 7, Issue 7, July 2026.Under physiological conditions, pathogenic stimuli activate TLR/IL1‐R signaling, triggering TOLLIP dissociation from IRAK1 and subsequent IRAK1 phosphorylation, TRAF6 ubiquitination, and NF‐κB activation. During SARS‐CoV‐2 infection, viral M protein binds TOLLIP and stabilizes the TOLLIP–IRAK1 complex, thereby suppressing NF‐κB signaling, impairing ...
Yabin Zhang +10 more
wiley +1 more source
The pivotal role of β‐lactone stereochemistry in the development of SARS‐CoV‐2 Mpro inhibitors
Protein Science, Volume 35, Issue 7, July 2026.Abstract From the arrival of the SARS‐CoV‐2 coronavirus in 2019 and its associated COVID‐19 pandemic, worldwide efforts have been focused on developing a drug to treat patients. The SARS‐CoV‐2 main protease (Mpro) is one of the main targets for drug design due to its key role in the virus replication and its distinguished ability to cleave peptides ...
Katarzyna Świderek, Vicent Moliner
wiley +1 more source
Influenza and Other Respiratory Viruses, Volume 20, Issue 7, July 2026.ABSTRACT Background The 8th International Society for Respiratory Viruses (ISRV) Antiviral Group Conference, held jointly with the 3rd International Meeting on Respiratory Pathogens in Singapore (17–20 September 2025), examined evolving approaches to prevention and management of respiratory infections.
Narmadha Morvil +5 more
wiley +1 more source
Viruses, 2023 Nirmatrelvir, which targets the SARS-CoV-2 main protease (Mpro), is the first-in-line drug for prevention and treatment of severe COVID-19, and additional Mpro inhibitors are in development.
Karen Anbro Gammeltoft +11 more
doaj +1 more source
Clinical Case Reports, Volume 14, Issue 6, June 2026.ABSTRACT This 35‐month case report documents irreversible physiological reserve depletion in a centenarian multimorbid man after COVID‐19. Prior to infection, he maintained precarious homeostasis for 17 years despite severe frailty (CFS 7), with stable CKD stage 3a (eGFR 58.3 mL/min/1.73 m2) and albumin 36.2 g/L.
Shan Xu +5 more
wiley +1 more source
<p>Analysis code for the study "Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12-17 years following SARS-CoV-2 Omicron infection: A target trial emulation"</p ...
IvanAuHKU
core +1 more source
A 1-pot synthesis of the SARS-CoV-2 Mpro Inhibitor Nirmatrelvir, the key ingredient in Paxlovid
, 2022 A newly devised route to the Pfizer drug nirmatrelvir is reported that reduces the overall sequence to a 1-pot process and relies on a commercially available, green coupling reagent, T3P.
Rahul, Kavthe +4 more
core +1 more source
Clinical and Translational Science, Volume 19, Issue 6, June 2026.Overview of patient centric microsampling approach for monitoring respiratory biomarkers for treatment optimization. Image created in BioRender. Khan, A. (2026) https://BioRender.com/17jm5cs. ABSTRACT The clinical heterogeneity of respiratory disorders emphasizes the need for personalized approaches to prevention, diagnosis, and therapy.
Ahmar Khan +4 more
wiley +1 more source
Chemoenzymatic Multicomponent Synthesis of Nirmatrelvir
, 2022 We report a new synthesis of the Covid-19 drug nirmatrelvir featuring a highly enantioselective biocatalytic desymmetrization and a diastereoselective multicomponent reaction as the key steps.
Ashleigh J., Burke +11 more
core +1 more source
Clinical and Translational Science, Volume 19, Issue 6, June 2026.ABSTRACT QT interval prolongation associated with drug administration is an important consideration in drug development. Patients with COVID‐19 are at increased risk for cardiac complications, and QT interval prolongation correlates with higher mortality.
Chi‐Chi Peng +6 more
wiley +1 more source